Broad-Spectrum ASMs
Broad-spectrum antiseizure medications (ASMs) are effective against both focal and generalized seizure types, making them the preferred choice when the epilepsy classification is uncertain or when patients have multiple seizure types. Five ASMs dominate this category in contemporary practice: valproate, levetiracetam, lamotrigine, topiramate, and zonisamide. Each offers a distinct balance of efficacy, tolerability, pharmacokinetic profile, and safety considerations that must be weighed during treatment selection. Brivaracetam, a newer SV2A ligand related to levetiracetam, has emerged as an important alternative with potentially fewer behavioral side effects. Understanding the nuances of each agent—including drug interactions, teratogenicity, and effects on comorbidities—is essential for individualized epilepsy management.
Bottom Line
- Valproate: Most effective ASM for idiopathic generalized epilepsy (IGE), including absence and myoclonic seizures; contraindicated in females of childbearing potential due to very high teratogenicity (>8% major malformations, decreased IQ, increased autism risk); multiple mechanisms (sodium channel, T-type calcium channel, GABA enhancement)
- Levetiracetam: Broad-spectrum SV2A ligand with no hepatic metabolism, no significant drug interactions, and rapid titration; the only ASM with Class I evidence for myoclonic seizures; behavioral side effects (irritability, depression) in 10–15% of patients; brivaracetam is an alternative with fewer behavioral effects
- Lamotrigine: Best first-line ASM for focal epilepsy (SANAD I and II); effective for GTC seizures; low teratogenicity; requires slow 6–8 week titration to avoid rash; Stevens-Johnson syndrome/TEN risk increased with rapid titration, valproate co-administration, and prior rash with carbamazepine/phenytoin
- Topiramate: Effective for focal and GTC seizures, migraine prophylaxis, and weight loss; limited by cognitive adverse effects (word-finding difficulty, impaired memory, decreased verbal fluency); intermediate teratogenicity (oral clefts, autism risk)
- Zonisamide: Broad-spectrum with long half-life (~60 hours) allowing once-daily dosing; cognitive effects are less pronounced than topiramate; kidney stones in up to 4%
Valproate (Valproic Acid / Divalproex Sodium)
Mechanism of Action
Valproate has multiple mechanisms of action, including potentiation of GABA-mediated inhibition, blockade of T-type calcium channels (predictive of efficacy against absence seizures), and blockade of voltage-gated sodium channels. This multi-target profile explains its broad-spectrum efficacy.
Pharmacokinetics
- Bioavailability: Almost complete; slightly less for extended-release formulation
- Protein binding: ~90% (high); free fraction increases with rising total concentration and with concurrent phenytoin use
- Metabolism: Extensive hepatic metabolism via conjugation and oxidation
- Half-life: 13–16 hours (adults); shortened to ~9 hours with enzyme-inducing co-medications
- Interactions: Potent enzyme inhibitor—reduces clearance of lamotrigine (doubles its half-life), phenobarbital, rufinamide, and carbamazepine epoxide
Efficacy
Valproate has the broadest spectrum of efficacy of any ASM, effective against all focal and generalized seizure types including absence and myoclonic seizures. It is the most effective ASM for IGE (SANAD I and II). Additional FDA indications include migraine prophylaxis and bipolar disorder. However, a large VA study found it less well tolerated and less effective than carbamazepine for focal impaired awareness seizures, though equally effective for focal to bilateral tonic-clonic seizures.
Dosing
- Starting dose: 500 mg at bedtime (extended-release divalproex) or 250 mg twice daily (delayed/immediate-release)
- Titration: Increase by 250–500 mg/wk as needed
- Target dose: 1000–2000 mg/d
- Therapeutic range: 50–100 μg/mL; check free levels at high concentrations or when free fraction is expected to be elevated
Adverse Effects
Valproate: Critical Safety Concerns
- Teratogenicity: Highest of any marketed ASM; dose-related major malformation rate >8% (exceeding 20% at doses >1500 mg/d); in utero exposure is associated with dose-dependent reduced verbal IQ, other cognitive dysfunction, and increased risk of autism spectrum disorder—should be avoided in all females of childbearing potential
- Hepatotoxicity: Idiosyncratic, potentially fatal hepatic failure; risk factors include polytherapy, young age (<2 years), and mitochondrial disease (especially POLG mutations—screen before initiating valproate in suspected mitochondrial disease)
- Pancreatitis: Rare but potentially life-threatening; can occur at any time during therapy
- Hyperammonemic encephalopathy: May occur in polytherapy (especially with topiramate); check ammonia levels in patients with unexplained confusion or cognitive decline on valproate
Common dose-related adverse effects include gastric irritation (nausea, vomiting, anorexia), tremor, weight gain, hair loss (alopecia), peripheral edema, fatigue, and drowsiness. Endocrine effects in women include polycystic ovary syndrome, hyperandrogenism, and insulin resistance. Dose-related thrombocytopenia may occur. Reversible parkinsonism, gait disorder, cognitive decline, and brain atrophy have been described with chronic use in older adults.
Levetiracetam
Mechanism of Action
Levetiracetam binds to the synaptic vesicle protein SV2A, resulting in a nonspecific decrease in neurotransmitter release during neuronal hyperactivation. This unique mechanism distinguishes it from traditional ASMs.
Pharmacokinetics
- Bioavailability: Excellent oral bioavailability
- Protein binding: Very low
- Metabolism: No hepatic metabolism; 66% excreted unchanged in urine, remainder hydrolyzed to inactive compounds
- Half-life: 6–8 hours
- Interactions: No known significant pharmacokinetic interactions—a major clinical advantage
Efficacy
Levetiracetam is a broad-spectrum ASM effective against focal seizures, generalized tonic-clonic seizures, and generalized myoclonic seizures. It is the only ASM with Class I evidence for efficacy against myoclonic seizures, making it particularly valuable in juvenile myoclonic epilepsy (JME), especially in females for whom valproate should be avoided. In SANAD II, it was noninferior to lamotrigine for time to treatment failure in focal epilepsy but inferior for time to 12-month remission.
Dosing
- Starting dose: 500 mg/d in 2 divided doses or once at bedtime (extended-release)
- Titration: Increase by 500 mg/wk as needed; post hoc analyses suggest efficacy is already maximal at the initial titration dose, so upward adjustments should be limited when no benefit is seen
- Target dose: 1000 mg/d; maximum 3000–4000 mg/d
Adverse Effects
Somnolence, dizziness, and asthenia are common. The most clinically significant adverse effects are behavioral and psychiatric:
- Irritability and hostility: More common in children; reported in approximately 10–15% of patients
- Depression and anxiety: May occur; rarely psychosis
- Teratogenicity: Low (≤3% major malformation rate with >2100 monotherapy exposures)
Brivaracetam: The SV2A Alternative
- Structurally related to levetiracetam with ~20-fold higher SV2A binding affinity and greater selectivity; higher brain permeability
- FDA-approved for focal seizures (ages ≥4 years); open-label data support efficacy for generalized seizure types, particularly JME
- Starting dose: 50 mg twice daily; dose range 25–100 mg twice daily
- Key advantage: Behavioral adverse effects (irritability) reported in only 3.2% of brivaracetam patients vs. 1.1% placebo; improvement or resolution of behavioral side effects reported in the majority switching from levetiracetam to brivaracetam
- Limitation: NOT effective when added to levetiracetam (both bind SV2A); should be used as a replacement, not an add-on, for levetiracetam
- Has more interactions than levetiracetam: clearance increased by enzyme inducers; may increase carbamazepine epoxide and phenytoin levels (up to 20%)
- IV formulation has been explored for status epilepticus due to superior brain permeability
Lamotrigine
Mechanism of Action
Lamotrigine blocks sodium channels similarly to phenytoin and carbamazepine but is thought to have additional unrecognized mechanisms that explain its efficacy against absence seizures, which traditional sodium channel blockers lack.
Pharmacokinetics
- Bioavailability: Excellent
- Protein binding: Not clinically significant (~55%)
- Metabolism: Extensive hepatic glucuronidation, then renal elimination
- Half-life: ~24 hours in monotherapy; approximately doubled (~48–60 hours) with valproate; approximately halved (~12 hours) with enzyme inducers
- Critical interaction: Estrogen and pregnancy increase lamotrigine clearance, potentially causing seizure breakthrough; monthly level monitoring during pregnancy is recommended
Efficacy
Lamotrigine is a broad-spectrum ASM effective against focal seizures, generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. SANAD I and SANAD II established it as the best first-line monotherapy for focal epilepsy based on the balance of efficacy and tolerability. It is less effective than valproate and ethosuximide for generalized absence seizures and less effective than valproate for IGE overall. It may be effective against myoclonic seizures in some patients but may exacerbate them in others.
Dosing
Lamotrigine: Mandatory Slow Titration
- Lamotrigine requires the slowest titration of any commonly used ASM to avoid potentially fatal rash (Stevens-Johnson syndrome/toxic epidermal necrolysis)
- Monotherapy: 25 mg/d for 2 weeks → 50 mg/d for 2 weeks → 100 mg/d → increase by 100 mg q2wk to target of 200–300 mg/d
- With valproate: Titration rate is HALF as fast (start 12.5–25 mg every other day) because valproate doubles lamotrigine levels
- With enzyme inducers (no valproate): Titration can be TWICE as fast because inducers halve lamotrigine levels
- The extended-release preparation allows once-daily dosing and reduces toxicity from peak levels
- Rash incidence: ~3% overall; higher in children, with concurrent valproate, and with rapid titration; risk also increased in patients with prior rash on carbamazepine or phenytoin
Adverse Effects
Dose-related adverse effects include dizziness, blurred vision, diplopia, unsteadiness, nausea, headache, and tremor. A key advantage is that lamotrigine is less sedating and has fewer cognitive adverse effects than most traditional ASMs. Its low teratogenicity rate (≤3% with >7000 monotherapy exposures) makes it a preferred choice for women of childbearing potential.
The Lamotrigine-Valproate Synergy
- The combination of lamotrigine and valproate has the strongest evidence of synergistic efficacy among ASM combinations—greater benefit than predicted from individual drug effects
- This synergy must be balanced against the pharmacokinetic interaction: valproate inhibits lamotrigine glucuronidation, doubling its half-life and levels
- Practical approach: Use lower lamotrigine doses (typically 100–200 mg/d) when combined with valproate; monitor for rash, especially during titration
- This combination is particularly useful in refractory generalized epilepsy when neither agent alone achieves seizure freedom
Topiramate
Mechanism of Action
Topiramate has multiple mechanisms: antagonism of AMPA/kainate glutamate receptors, augmentation of GABA activity, blockade of voltage-gated sodium channels, and weak carbonic anhydrase inhibition (which contributes to side effects but not to efficacy).
Pharmacokinetics
- Bioavailability: Excellent
- Protein binding: Not clinically significant
- Metabolism: Partially hepatic (~30%); ~70% eliminated unchanged in urine
- Half-life: ~21 hours
- Interactions: Mild CYP3A4 inducer (reduces oral contraceptive efficacy at ≥200 mg/d); mild CYP2C19 inhibitor
Efficacy
Topiramate is FDA-approved for monotherapy and adjunctive therapy for focal seizures and generalized tonic-clonic seizures, adjunctive therapy for Lennox-Gastaut syndrome, and migraine prophylaxis. It is also used as a weight-loss agent (combined with phentermine). A pilot trial suggested it is not effective for generalized absence seizures. In SANAD I, topiramate was the least well tolerated of the five agents tested for focal epilepsy.
Dosing
- Starting dose: 25 mg/d (must be titrated slowly to manage cognitive effects)
- Titration: Increase by 25 mg/wk
- Target dose: 100 mg/d; maximum 400 mg/d in 2 divided doses
- Extended-release preparations with once-daily dosing may improve tolerability
Adverse Effects
Topiramate: Cognitive and Teratogenic Concerns
- Cognitive adverse effects are the primary tolerability limitation: cognitive slowing, decreased attention and memory, impaired executive function, word-finding difficulty, reduced verbal fluency—patients may not be aware of these deficits
- Teratogenicity: Intermediate risk (~4% major malformations); increased oral clefts; in utero exposure associated with low birth weight, increased risk of autism spectrum disorder and intellectual disability—avoid in females of childbearing potential when alternatives exist
- Kidney stones: ~1.5% of patients (carbonic anhydrase inhibition effect)
- Metabolic acidosis: More common in children; can cause oligohidrosis and hyperthermia
- Hyperammonemia: May occur when topiramate is combined with valproate
- Acute myopia and angle-closure glaucoma: Rare but potentially serious; typically occurs within the first month
Other adverse effects include sedation, fatigue, dizziness, ataxia, depression, and paresthesias (hands and feet, from carbonic anhydrase inhibition—usually transient). Decreased appetite and weight loss are common and may be advantageous in patients with obesity.
Zonisamide
Mechanism of Action
Zonisamide has multiple mechanisms including blockade of T-type calcium channels (predictive of absence seizure efficacy), blockade of sodium channels, and weak carbonic anhydrase inhibition. It is structurally related to sulfonamides.
Pharmacokinetics
- Bioavailability: Excellent
- Protein binding: Not clinically significant
- Metabolism: Hepatic to inactive metabolites (~65%)
- Half-life: ~60 hours—the longest of any commonly used ASM; allows once-daily dosing and reduces the impact of missed doses
- Interactions: Not an enzyme inducer or inhibitor (a pharmacokinetic advantage)
Efficacy
Zonisamide is considered a broad-spectrum ASM, although Class I trials have only been conducted in focal seizures. In Japan, it is approved for generalized seizures as well. The SANAD II trial favored lamotrigine over zonisamide as first-line treatment for focal epilepsy, and it is rarely chosen as a first-line agent.
Dosing
- Starting dose: 100 mg at bedtime for 2 weeks, then 200 mg at bedtime
- Titration: Increase by 100 mg q1–2wk as needed
- Target dose: 200 mg/d; maximum 600 mg/d (once daily or divided)
- Therapeutic range: 10–40 μg/mL
Adverse Effects
Sedation, ataxia, dizziness, nausea, fatigue, agitation, irritability, and anorexia. Cognitive slowing and difficulty with concentration may occur, particularly at higher doses, but are less pronounced than with topiramate. Weight loss may occur. Kidney stones develop in up to 4% (adequate hydration may help prevent). Rare serious adverse effects include SJS/TEN, depression, psychosis, oligohidrosis, and metabolic acidosis.
Comparative Overview
| Feature | Valproate | Levetiracetam | Lamotrigine | Topiramate | Zonisamide |
|---|---|---|---|---|---|
| Focal seizures | Class I | Class I | Class I | Class I | Class I |
| GTC seizures | Suggested | Class I | Class I | Class I | Suggested |
| Absence seizures | Class I | Suggested | Suggested | Not effective | Suggested |
| Myoclonic seizures | Suggested | Class I | Variable | Unknown | Suggested |
| Half-life (hours) | 13–16 | 6–8 | ~24 | ~21 | ~60 |
| Protein binding | High (90%) | Low | Intermediate | Low | Low |
| Drug interactions | High (inhibitor) | None/minimal | Moderate | None/minimal | Moderate |
| Teratogenicity | Very high (>8%) | Low (≤3%) | Low (≤3%) | Intermediate (~4%) | Low (≤3%) |
| Weight effect | Gain | Neutral | Neutral | Loss | Loss |
| Cognitive effects | Moderate | Minimal | Minimal | Significant | Moderate |
| Mood effects | Stabilizer | Irritability, depression | Stabilizer (bipolar I) | Depression | Irritability |
| IV formulation | Yes | Yes | No | No | No |
| ASM | Best Suited For | Avoid In |
|---|---|---|
| Valproate | Males with IGE (absence, myoclonic, GTC); refractory generalized epilepsy; migraine comorbidity | Females of childbearing potential; hepatic disease; mitochondrial disease (POLG); elderly (reversible parkinsonism) |
| Levetiracetam | Broad-spectrum first-line when rapid titration needed; JME in females; polypharmacy patients (no interactions); IV use in status epilepticus | Patients with preexisting mood/behavioral disorders (depression, irritability); consider brivaracetam as alternative |
| Lamotrigine | First-line focal epilepsy; women of childbearing potential; bipolar comorbidity; patients needing minimal cognitive effects | Situations requiring urgent seizure control (6–8 week titration); caution with valproate co-administration (rash risk) |
| Topiramate | Focal/GTC with migraine comorbidity; patients with obesity; LGS | Patients requiring cognitive acuity (students, professionals); females of childbearing potential; nephrolithiasis |
| Zonisamide | Adjunctive therapy; patients with adherence concerns (long half-life, once daily); weight-neutral/loss desired | Patients with cognitive concerns (though better than topiramate); history of kidney stones; sulfonamide allergy |
References
- Abou-Khalil B. Update on antiseizure medications 2025. Continuum (Minneap Minn) 2025;31(1):123–165.
- Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy. Lancet 2007;369(9566):1000–1015.
- Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy. Lancet 2007;369(9566):1016–1026.
- Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy. Lancet 2021;397(10282):1375–1386.
- Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010;362(9):790–799.
- Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy. Neurology 2015;85(10):866–872.
- Christensen J, Grønborg TK, Sørensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013;309(16):1696–1703.
- Cohen JM, Alvestad S, Cesta CE, et al. Comparative safety of antiseizure medication monotherapy for major malformations. Ann Neurol 2023;93:551–562.
- Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study). Lancet Neurol 2013;12(3):244–252.
- Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327(11):765–771.